Candel Therapeutics Files 8-K
Ticker: CADL · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1841387
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Candel Therapeutics dropped an 8-K, check it for updates.
AI Summary
Candel Therapeutics, Inc. filed an 8-K on December 11, 2024, to report on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. Specific details regarding the nature of these events or any financial figures were not immediately available in the provided text.
Why It Matters
This 8-K filing indicates that Candel Therapeutics is disclosing material information to the public, which could impact investor understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- December 11, 2024 (date) — Date of Report
- 001-40629 (other) — Commission File Number
- 52-2214851 (other) — IRS Employer Identification No.
- Needham, MA (location) — Principal Executive Offices
FAQ
What specific events are being disclosed under Regulation FD?
The provided text does not specify the exact nature of the Regulation FD Disclosure events.
What are the 'Other Events' reported by Candel Therapeutics?
The filing indicates 'Other Events' were reported, but the specific details are not present in the provided text.
What financial statements or exhibits are included with this 8-K filing?
The filing mentions 'Financial Statements and Exhibits' but does not list their specific contents.
When was Candel Therapeutics, Inc. incorporated or organized?
The company was incorporated in Delaware, as indicated by the filing.
What is the principal executive office address for Candel Therapeutics?
The principal executive offices are located at 117 Kendrick St., Suite 450, Needham, MA 02494.
Filing Stats: 1,263 words · 5 min read · ~4 pages · Grade level 11.4 · Accepted 2024-12-11 07:45:07
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share CADL The Nasdaq
Filing Documents
- d901922d8k.htm (8-K) — 37KB
- d901922dex991.htm (EX-99.1) — 27KB
- d901922dex992.htm (EX-99.2) — 44KB
- g901922ex99_2p10g1.jpg (GRAPHIC) — 330KB
- g901922ex99_2p11g1.jpg (GRAPHIC) — 156KB
- g901922ex99_2p12g1.jpg (GRAPHIC) — 327KB
- g901922ex99_2p13g1.jpg (GRAPHIC) — 321KB
- g901922ex99_2p14g1.jpg (GRAPHIC) — 251KB
- g901922ex99_2p15g1.jpg (GRAPHIC) — 298KB
- g901922ex99_2p16g1.jpg (GRAPHIC) — 333KB
- g901922ex99_2p17g1.jpg (GRAPHIC) — 289KB
- g901922ex99_2p18g1.jpg (GRAPHIC) — 271KB
- g901922ex99_2p19g1.jpg (GRAPHIC) — 218KB
- g901922ex99_2p1g1.jpg (GRAPHIC) — 221KB
- g901922ex99_2p20g1.jpg (GRAPHIC) — 254KB
- g901922ex99_2p21g1.jpg (GRAPHIC) — 205KB
- g901922ex99_2p22g1.jpg (GRAPHIC) — 388KB
- g901922ex99_2p23g1.jpg (GRAPHIC) — 164KB
- g901922ex99_2p24g1.jpg (GRAPHIC) — 336KB
- g901922ex99_2p25g1.jpg (GRAPHIC) — 120KB
- g901922ex99_2p26g1.jpg (GRAPHIC) — 272KB
- g901922ex99_2p27g1.jpg (GRAPHIC) — 174KB
- g901922ex99_2p28g1.jpg (GRAPHIC) — 83KB
- g901922ex99_2p29g1.jpg (GRAPHIC) — 309KB
- g901922ex99_2p2g1.jpg (GRAPHIC) — 568KB
- g901922ex99_2p30g1.jpg (GRAPHIC) — 245KB
- g901922ex99_2p31g1.jpg (GRAPHIC) — 121KB
- g901922ex99_2p32g1.jpg (GRAPHIC) — 389KB
- g901922ex99_2p33g1.jpg (GRAPHIC) — 236KB
- g901922ex99_2p34g1.jpg (GRAPHIC) — 313KB
- g901922ex99_2p35g1.jpg (GRAPHIC) — 207KB
- g901922ex99_2p36g1.jpg (GRAPHIC) — 378KB
- g901922ex99_2p37g1.jpg (GRAPHIC) — 107KB
- g901922ex99_2p38g1.jpg (GRAPHIC) — 298KB
- g901922ex99_2p39g1.jpg (GRAPHIC) — 431KB
- g901922ex99_2p3g1.jpg (GRAPHIC) — 118KB
- g901922ex99_2p40g1.jpg (GRAPHIC) — 549KB
- g901922ex99_2p41g1.jpg (GRAPHIC) — 328KB
- g901922ex99_2p4g1.jpg (GRAPHIC) — 419KB
- g901922ex99_2p5g1.jpg (GRAPHIC) — 157KB
- g901922ex99_2p6g1.jpg (GRAPHIC) — 346KB
- g901922ex99_2p7g1.jpg (GRAPHIC) — 373KB
- g901922ex99_2p8g1.jpg (GRAPHIC) — 234KB
- g901922ex99_2p9g1.jpg (GRAPHIC) — 350KB
- g901922g1211112939011.jpg (GRAPHIC) — 5KB
- 0001193125-24-274870.txt ( ) — 16093KB
- cadl-20241211.xsd (EX-101.SCH) — 2KB
- cadl-20241211_lab.xml (EX-101.LAB) — 18KB
- cadl-20241211_pre.xml (EX-101.PRE) — 11KB
- d901922d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated December 11, 2024 99.2 Presentation dated December 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: December 11, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer